BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36542759)

  • 1. Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
    Wang MS; Wang ZZ; Li ZL; Gong Y; Duan CX; Cheng QH; Huang W; Yang GF
    J Med Chem; 2023 Jan; 66(1):611-626. PubMed ID: 36542759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.
    Zeng S; Zeng M; Yuan S; He L; Jin Y; Huang J; Zhang M; Yang M; Pan Y; Wang Z; Chen Y; Xu X; Huang W
    Bioorg Chem; 2023 Oct; 139():106728. PubMed ID: 37536217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.
    Zhang J; Li Y; Tang H; Zhou Q; Tong L; Ding J; Xie H; Xiong B; Liu T
    Bioorg Chem; 2023 Nov; 140():106811. PubMed ID: 37659145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
    Wu F; Li H; An Q; Sun Y; Yu J; Cao W; Sun P; Diao X; Meng L; Xu S
    Eur J Med Chem; 2023 Jun; 254():115355. PubMed ID: 37062169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of small-molecule inhibitors targeting HPK1.
    Zhou L; Wang T; Zhang K; Zhang X; Jiang S
    Eur J Med Chem; 2022 Dec; 244():114819. PubMed ID: 36209628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
    You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
    Zeng S; Wu M; Jin Y; Ye Y; Xia H; Chen X; Che J; Wang Z; Wu Y; Dong X; Chen Y; Huang W
    Eur J Med Chem; 2024 Mar; 267():116206. PubMed ID: 38350360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1.
    Zhou L; Ye X; Wang K; Shen H; Wang T; Zhang X; Jiang S; Xiao Y; Zhang K
    Bioorg Chem; 2023 Sep; 138():106682. PubMed ID: 37339563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
    Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
    Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.
    Malchow S; Korepanova A; Panchal SC; McClure RA; Longenecker KL; Qiu W; Zhao H; Cheng M; Guo J; Klinge KL; Trusk P; Pratt SD; Li T; Kurnick MD; Duan L; Shoemaker AR; Gopalakrishnan SM; Warder SE; Shotwell JB; Lai A; Sun C; Osuma AT; Pappano WN
    ACS Chem Biol; 2022 Mar; 17(3):556-566. PubMed ID: 35188729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.
    Wang Y; Zhang K; Georgiev P; Wells S; Xu H; Lacey BM; Xu Z; Laskey J; Mcleod R; Methot JL; Bittinger M; Pasternak A; Ranganath S
    PLoS One; 2020; 15(12):e0243145. PubMed ID: 33270695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
    Shi H; Tang H; Li Y; Chen D; Liu T; Chen Y; Wang X; Chen L; Wang Y; Xie H; Xiong B
    Eur J Med Chem; 2023 Feb; 248():115064. PubMed ID: 36621137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
    Hernandez S; Qing J; Thibodeau RH; Du X; Park S; Lee HM; Xu M; Oh S; Navarro A; Roose-Girma M; Newman RJ; Warming S; Nannini M; Sampath D; Kim JM; Grogan JL; Mellman I
    Cell Rep; 2018 Oct; 25(1):80-94. PubMed ID: 30282040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation.
    Alzabin S; Bhardwaj N; Kiefer F; Sawasdikosol S; Burakoff S
    J Immunol; 2009 May; 182(10):6187-94. PubMed ID: 19414772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors.
    Fu S; Wei J; Li C; Zhang N; Yue H; Yang A; Xu J; Dong K; Xing Y; Tong M; Shi X; Xi Z; Wang H; Hou Y; Zhao Y
    Bioorg Chem; 2024 May; 148():107454. PubMed ID: 38795581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
    Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Taniguchi T; Umezaki Y; Nakazawa Y; Uesugi S; Mori K; Horiuchi T; Obuchi W; Minami M; Shimada T; Wada C; Yoshida T; Higuchi S
    Eur J Pharmacol; 2023 Dec; 961():176184. PubMed ID: 37944847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors.
    Xie C; Liu B; Song Z; Yang Y; Dai M; Gao Y; Yao Y; Ding C; Ai J; Zhang A
    J Med Chem; 2023 Dec; 66(23):16201-16221. PubMed ID: 37990878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPK1 as a novel target for cancer immunotherapy.
    Sawasdikosol S; Zha R; Yang B; Burakoff S
    Immunol Res; 2012 Dec; 54(1-3):262-5. PubMed ID: 22477524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).
    Linney ID; Kaila N
    Expert Opin Ther Pat; 2021 Oct; 31(10):893-910. PubMed ID: 33956554
    [No Abstract]   [Full Text] [Related]  

  • 20. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
    Zhu Q; Chen N; Tian X; Zhou Y; You Q; Xu X
    J Med Chem; 2022 Jun; 65(12):8065-8090. PubMed ID: 35696642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.